Lusutrombopag

Lusutrombopag Brand Name– MULPLETA

What is Lusutrombopag

Lusutrombopag is an oral thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Lusutrombopag is not appropriate for use to normalize platelet counts in patients with chronic liver disease. Clinical trials enrolled patients with chronic liver disease who were undergoing an invasive procedure and had a platelet count less than 50 x 109/L.

Lusutrombopag treatment was associated with significantly more patients achieving a platelet count more than 50 x 109/L or a platelet count increase of 20 x 109/L or more from baseline and avoiding a platelet transfusion prior to the invasive procedure.

TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease; the potential increased thrombotic risk must be considered when administering lusutrombopag to patients with known risk factors for thromboembolism.

Indications

  • chronic liver disease-associated thrombocytopenia

For the treatment of chronic liver disease-associated thrombocytopenia in patients who are scheduled to undergo a procedure

Side Effects

  • headache
  • thrombosis

Headache was reported in 5% of lusutrombopag-treated patients (vs. 4% placebo) during clinical trials.

Monitoring Parameters

  • platelet count

Contraindications

  • breast-feeding
  • pregnancy
  • thromboembolic disease

Interactions

There are no drug interactions associated with Lusutrombopag products.

You cannot copy content of this page